Alali Ali A, Almadi Majid A, Martel Myriam, Barkun Alan N
Department of Medicine, Faculty of Medicine, Kuwait University, Jabriyah, Kuwait.
Division of Gastroenterology, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia.
Saudi J Gastroenterol. 2024 Jul 10;30(4):200-9. doi: 10.4103/sjg.sjg_86_24.
Cap-mounted-clips, especially Over-The-Scope-Clip (OTSC™), are recommended for recurrent nonvariceal upper gastrointestinal bleeding (NVUGIB). There has been recent interest in their use as an initial hemostatic modality. We performed a systematic review of randomized controlled trials (RCTs) assessing cap-mounted clips' efficacy as a primary hemostatic modality in NVUGIB.
A literature search of MEDLINE, EMBASE, and ISI Web of Science databases up to April 2024 identified RCTs comparing cap-mounted clips to standard endoscopic therapy (SET) as a primary hemostatic modality in NVUGIB. The primary endpoint was the composite outcome of further bleeding (persistent or recurrent) at 30 days. Secondary outcomes included persistent bleeding at index endoscopy and 30-day rebleeding, individually. Other pertinent outcomes were also recorded. A meta-analysis was performed to determine pooled risk ratios (RRs), comparing cap-mounted clip to SET. Out of 516 citations, five RCTs (n = 555), all assessing OTSC™, were included.
The composite outcome of further bleeding was lower with cap-mounted clip versus SET (RR = 0.33 [95% confidence interval {CI}: 0.20-0.54]). There was no difference in persistent bleeding at initial endoscopy (RR = 0.30 [95% CI: 0.07-1.30]), but 30-day rebleeding was lower with cap-mounted clip (RR = 0.38 [95% CI: 0.21-0.70]). There were no differences in other outcomes. Grading of the evidence ranged from very low to moderate, mainly due to risk of bias and imprecision.
Cap-mounted clips may be an efficacious primary hemostatic modality, associated with a lower further bleeding at 30 days compared to SET in NVUGIB. However, due to limitations in existing evidence, further research must better characterize an optimal subgroup of patients benefiting most from this approach before adopting its routine use.
帽式夹,尤其是内镜下圈套夹(OTSC™),被推荐用于复发性非静脉曲张性上消化道出血(NVUGIB)。近期人们对将其用作初始止血方式产生了兴趣。我们对评估帽式夹作为NVUGIB初始止血方式疗效的随机对照试验(RCT)进行了系统评价。
检索截至2024年4月的MEDLINE、EMBASE和ISI Web of Science数据库,以确定在NVUGIB中比较帽式夹与标准内镜治疗(SET)作为初始止血方式的RCT。主要终点是30天时进一步出血(持续性或复发性)的复合结局。次要结局包括初次内镜检查时的持续性出血和30天再出血,分别进行分析。还记录了其他相关结局。进行荟萃分析以确定帽式夹与SET相比的合并风险比(RRs)。在516篇文献中,纳入了5项RCT(n = 555),均评估了OTSC™。
与SET相比,帽式夹组进一步出血的复合结局更低(RR = 0.33 [95%置信区间{CI}:0.20 - 0.54])。初次内镜检查时的持续性出血无差异(RR = 0.30 [95% CI:0.07 - 1.30]),但帽式夹组30天再出血更低(RR = 0.38 [95% CI:0.21 - 0.70])。其他结局无差异。证据等级从极低到中等,主要是由于偏倚风险和不精确性。
帽式夹可能是一种有效的初始止血方式,与SET相比,在NVUGIB中30天时进一步出血更低。然而,由于现有证据的局限性,在常规使用这种方法之前,进一步的研究必须更好地确定最能从这种方法中获益的最佳患者亚组。